Mammographic Density as a Surrogate Marker for the Effects of Hormone Therapy on Risk of Breast Cancer

Open Access

Abstract

Background: Some types of hormone therapy increase both risk of breast cancer and mammographic density, a risk factor for the disease, suggesting that mammographic density may be a surrogate marker for the effects of hormones on risk of breast cancer. This research was undertaken to determine whether the effect of hormone therapy on breast cancer risk is mediated by its effect on mammographic density.

Keywords

BREAST CANCER

This publication has 23 references indexed in Scilit:

Use of menopausal hormones in the United States, 1992 through June, 2003
Pharmacoepidemiology and Drug Safety, 2004
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy
JAMA, 2004
Breast cancer and hormone-replacement therapy in the Million Women Study
The Lancet, 2003
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
JAMA, 2002
Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens
Climacteric, 2001
Effects of Estrogen and Estrogen–Progestin on Mammographic Parenchymal Density
Annals of Internal Medicine, 1999
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
The Lancet, 1997
Quantitative Classification of Mammographic Densities and Breast Cancer Risk: Results From the Canadian National Breast Screening Study
JNCI Journal of the National Cancer Institute, 1995
Changes in Mammographic Densities Induced by a Hormonal Contraceptive Designed to Reduce Breast Cancer Risk
JNCI Journal of the National Cancer Institute, 1994
Factors associated with mammographic pattern
The British Journal of Radiology, 1985

Cited by 58 articles